{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:53:03Z","timestamp":1792173183772,"version":"4.4.0"},"reference-count":49,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009566","name":"universitetet i oslo","doi-asserted-by":"publisher","award":["Financial support for this study was provided by t"],"award-info":[{"award-number":["Financial support for this study was provided by t"]}],"id":[{"id":"10.13039\/501100009566","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Med Decis Making"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Screening pregnant women for gestational diabetes mellitus (GDM) has recently been expanded in Norway, although screening eligibility criteria continue to be debated. We aimed to compare the cost-effectiveness of alternative GDM screening strategies and explored structural uncertainty and the value of future research in determining the most cost-effective eligibility criteria for GDM screening in Norway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>We developed a probabilistic decision tree to estimate the total costs and health benefits (i.e., quality-adjusted life-years; QALYs) associated with 4 GDM screening strategies (universal, current guidelines, high-risk, and no screening). We identified the most cost-effective strategy as the strategy with the highest incremental cost-effectiveness ratio below a Norwegian benchmark for cost-effectiveness ($28,400\/QALY). We excluded inconclusive evidence on the effects of screening on later maternal type 2 diabetes mellitus (T2DM) in the primary analysis but included this outcome in a secondary analysis using 2 different sources of evidence (i.e., Cochrane or US Preventive Services Task Force). To quantify decision uncertainty, we conducted scenario analysis and value-of-information analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Current screening recommendations were considered inefficient in all analyses, while universal screening was most cost-effective in our primary analysis ($26,014\/QALY gained) and remained most cost-effective when we assumed a preventive effect of GDM treatment on T2DM. When we assumed no preventive effect, high-risk screening was preferred ($19,115\/QALY gained). When we assumed GDM screening does not prevent perinatal death in scenario analysis, all strategies except no screening exceeded the cost-effectiveness benchmark. In most analyses, decision uncertainty was high.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The most cost-effective screening strategy, ranging from no screening to universal screening, depended on the source and inclusion of GDM treatment effects on perinatal death and T2DM. Further research on these long-term outcomes could reduce decision uncertainty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                    <jats:p>This article analyses the cost-effectiveness of 4 alternative gestational diabetes mellitus (GDM) screening strategies in Norway: universal screening, current (broad) screening, high-risk screening, and no screening. The current Norwegian screening recommendations were considered inefficient under all analyses. The most cost-effective screening strategy ranged from no screening to universal screening depending on the source and inclusion of GDM treatment effects on later maternal diabetes and perinatal death. The parameters related to later maternal diabetes and perinatal death accounted for most of the decision uncertainty.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0272989x241241339","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T04:50:24Z","timestamp":1712638224000},"page":"380-392","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Exploring Structural Uncertainty in Cost-Effectiveness Modeling of Gestational Diabetes Screening: An Application Example from Norway"],"prefix":"10.1177","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8252-6754","authenticated-orcid":false,"given":"Pia S.","family":"Henkel","sequence":"first","affiliation":[{"name":"Department of Health Management and Health Economics, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6657-5849","authenticated-orcid":false,"given":"Emily A.","family":"Burger","sequence":"additional","affiliation":[{"name":"Department of Health Management and Health Economics, University of Oslo, Oslo, Norway"},{"name":"Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"Sletner","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescents Medicine, Akershus University Hospital, L\u00f8renskog, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kine","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Department of Health Management and Health Economics, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"key":"bibr1-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0098-8"},{"key":"bibr2-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707943"},{"key":"bibr3-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.11628"},{"key":"bibr4-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.10404"},{"key":"bibr5-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.14276"},{"key":"bibr6-0272989X241241339","unstructured":"Helsedirektoratet. Svangerskapsdiabetes Nasjonal faglig retningslinje. Updated 10 January, 2022. Available from: https:\/\/www.helsedirektoratet.no\/retningslinjer\/svangerskapsdiabetes#referere. [Accessed 18 January, 2022]."},{"key":"bibr7-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-021-04086-9"},{"key":"bibr8-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007222.pub4"},{"key":"bibr9-0272989X241241339","unstructured":"Norwegian Ministry of Health and Care Services. Principles for priority setting in health care. 2017. Available from: https:\/\/www.regjeringen.no\/en\/dokumenter\/meld.st.34-20152016\/id2502758\/. [Accessed 20 April, 2022]."},{"key":"bibr10-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.04.014"},{"key":"bibr11-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.2188\/jea.JE20190338"},{"key":"bibr12-0272989X241241339","unstructured":"Pillay J, Donovan L, Guitard S, et al. Screening for Gestational Diabetes Mellitus: A Systematic Review to Update the 2014 U.S. Preventive Services Task Force Recommendation. AHRQ Publication No. 21-05273-EF-1. 2021. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK573100\/pdf\/Bookshelf_NBK573100.pdf"},{"key":"bibr13-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011970.pub2"},{"key":"bibr14-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.07.014"},{"key":"bibr15-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.3310\/hta20860"},{"key":"bibr16-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.01.001"},{"key":"bibr17-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-statistics-040120-010730"},{"key":"bibr18-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00502.x"},{"key":"bibr19-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"key":"bibr20-0272989X241241339","unstructured":"Statistics Norway. Population. Updated 19 May, 2022. Available from: https:\/\/www.ssb.no\/en\/befolkning\/folketall\/statistikk\/befolkning. [Accessed 23 May, 2022]."},{"key":"bibr21-0272989X241241339","unstructured":"Organisation for Economic Cooperation and Development. Purchasing power parities (PPP) (indicator). Available from: https:\/\/data.oecd.org\/conversion\/purchasing-power-parities-ppp.htm. [Accessed 22 October, 2022]."},{"key":"bibr22-0272989X241241339","unstructured":"Arbeidsgruppe nedsatt av Helse- og omsorgsdepartementet. P\u00e5 ramme alvor: Alvorlighet og prioritering. 2015. Available from: https:\/\/www.regjeringen.no\/contentassets\/d5da48ca5d1a4b128c72fc5daa3b4fd8\/paa_ramme_alvor.pdf. [Accessed 23 May, 2022]."},{"key":"bibr23-0272989X241241339","unstructured":"Norwegian Institute of Public Health. Guidelines for the submission of documentation for single technology assessments (STAs) of medical devices and diagnostic interventions. 2021. Available from: https:\/\/www.fhi.no\/globalassets\/guidelines-for-the-submission-of-documents-for-stas-2021.pdf. [Accessed 19 January, 2022]."},{"key":"bibr24-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X13505910"},{"key":"bibr25-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175288"},{"key":"bibr26-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00844-y"},{"key":"bibr27-0272989X241241339","unstructured":"Data from: Medical Birth Registry [aggregated data provided upon request]. 2022. Deposited February 14, 2022 and March 25, 2022."},{"key":"bibr28-0272989X241241339","unstructured":"Norwegian Institute of Public Health. Medical Birth Registry of Norway. Updated 16 December, 2019. Available from: https:\/\/www.fhi.no\/en\/hn\/health-registries\/medical-birth-registry-of-norway\/medical-birth-registry-of-norway\/. [Accessed 11 May, 2022]."},{"key":"bibr29-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2150-4"},{"key":"bibr30-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3824-0"},{"key":"bibr31-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229496"},{"key":"bibr32-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4506-x"},{"key":"bibr33-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.117.008337"},{"key":"bibr34-0272989X241241339","unstructured":"Helsedirektoratet. Regelverk for innsatsstyrt finansiering 2021 (ISF-regelverket). 2020. Available from: https:\/\/www.helsedirektoratet.no\/tema\/finansiering\/innsatsstyrt-finansiering-og-drg-systemet\/innsatsstyrt-finansiering-isf\/ISF-regelverket%202021.pdf\/_\/attachment\/inline\/3e084cec-bce9-4a44-89f0-f8d179b4e478:5229e063e72719e76f57316d73d45ee57fb60a96\/ISF-regelverket%202021.pdf. [Accessed 19 March, 2022]."},{"key":"bibr35-0272989X241241339","unstructured":"Legeforeningen. Takster for allmennpraktiserende lege i fastlegeordningen. 2021. Available from: https:\/\/normaltariffen.legeforeningen.no\/asset\/pdf\/Fastlegetariffen-2021-2022.pdf. [Accessed 30 March, 2024]."},{"key":"bibr36-0272989X241241339","unstructured":"Norwegian Medical Products Agency. Price- and reimbursement list. Updated 6 January, 2022. Available from: https:\/\/www.dmp.no\/en\/public-funding-and-pricing-of-medicines\/pricing-of-medicines\/maximum-price. [Original price list accessed from Statens legemiddelverk 19 March, 2022]."},{"key":"bibr37-0272989X241241339","unstructured":"Senter for klinisk dokumentasjon og evaluering. Helseatlas for f\u00f8dselshjelp 2015-2017. 2019. Available from: https:\/\/helseatlas.no\/sites\/default\/files\/helseatlas-fodselshjelp.pdf. [Accessed 16 March, 2022]."},{"key":"bibr38-0272989X241241339","unstructured":"Senter for klinisk dokumentasjon og evaluering. The Norwegian Neonatal Healthcare Atlas, 2009-2014. 2016. Available from: https:\/\/helseatlas.no\/sites\/default\/files\/norwegian-neonatal-healthcare.pdf. [Accessed 12 April, 2022.]"},{"key":"bibr39-0272989X241241339","unstructured":"Helsedirektoratet. Svangerskapsomsorgen Nasjonal faglig retningslinje. Updated 10 November, 2021. Available from: https:\/\/www.helsedirektoratet.no\/retningslinjer\/svangerskapsomsorgen. [Accessed 10 June, 2022]."},{"key":"bibr40-0272989X241241339","unstructured":"Oslo Economics. Screening for svangerskapsdiabetes: En helse\u00f8konomisk analyse av alternative m\u00e5lgrupper for screening. 2021. Available from: https:\/\/osloeconomics.no\/en\/publication\/screening-for-svangerskapsdiabetes\/. [Accessed 18 January, 2022.]"},{"key":"bibr41-0272989X241241339","unstructured":"Statistics Norway. Konsumprisindeks, historisk serie fra 1924 (2015=100). Available from: https:\/\/www.ssb.no\/priser-og-prisindekser\/konsumpriser\/statistikk\/konsumprisindeksen. [Accessed 19 March, 2022.]"},{"key":"bibr42-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7058082"},{"key":"bibr43-0272989X241241339","unstructured":"Statistics Norway. 05375: Life expectancy, by sex and age 1986 \u2013 2021. Available from: https:\/\/www.ssb.no\/en\/statbank\/table\/05375\/. [Accessed 19 May, 2022.]."},{"key":"bibr44-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-014-0290-2"},{"key":"bibr45-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002488"},{"key":"bibr46-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1848"},{"key":"bibr47-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18041423"},{"key":"bibr48-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2941"},{"key":"bibr49-0272989X241241339","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00686.x"}],"container-title":["Medical Decision Making"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0272989X241241339","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0272989X241241339","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0272989X241241339","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:02:46Z","timestamp":1777658566000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0272989X241241339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1177\/0272989X241241339"],"URL":"https:\/\/doi.org\/10.1177\/0272989x241241339","relation":{},"ISSN":["0272-989X","1552-681X"],"issn-type":[{"value":"0272-989X","type":"print"},{"value":"1552-681X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]}}}